NCEL · NewcelX Ltd
United States · RS rating 24 · As of 2026-11-03
| Price | 2.64 USD |
|---|---|
| 1-day change | +6.0% |
| RS rating (overall / 1M / 3M / 12M) | 24 / 40 / 25 / 15 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 16 / 26 / 3 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | – |
| Distance from 52-week high | +53.3% |
| Market cap (USD) | $24.8M |